We are currently investigating the status of MDSCs/Treg in breast, ovarian, and prostate cancer patients receiving DPX-0907 and survivin-targeted DPX-Survivac peptide cancer vaccine in ovarian cancer patients. This evidence concerns the gene BIRC5 and prostate carcinoma.